Uveitis Treatment Market

The global uveitis treatment market accounted for USD 0.753 billion in 2023 and is expected to reach USD 1.34 billion by 2034 with a CAGR of 5.41% during the forecast period 2024-2034. The market will grow as a result of factors such as the increasing prevalence of uveitis, improvements in treatment technologies, an aging population, growing awareness and diagnosis, government initiatives and funding, and strategic alliances and collaborations.

The middle layer of the eye, the uvea, becomes inflamed when it has uveitis. It can result in blindness, discomfort, and issues with vision. Globally, uveitis is becoming more common as a result of aging populations, an increase in autoimmune illnesses, and more public awareness of the ailment. One of the main factors driving the market for uveitis treatments is the expanding patient base. For instance, in February 2024, Santen Pharmaceutical Co., Ltd. announced favorable Phase 3 trial results for the investigational medicine Sihprom (dexamethasone implant), which is used to treat non-infectious uveitis.

By treatment type, the corticosteroids segment accounted for the highest revenue-grossing segment in the global uveitis treatment market in 2023 owing to the high efficacy, widespread availability, and established use as first-line treatment options for uveitis management. For instance, in August 2023, Clearside Biomedical, Inc. submitted a New Drug Application (NDA) to the FDA for Xtiment, a sustained-delivery dexamethasone implant, to treat uveitis. Additionally, the monoclonal antibodies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for targeted therapies, advancements in biotechnology, and promising clinical trial results demonstrating efficacy in treating refractory uveitis cases.

By disease type, the anterior uveitis segment accounted for the highest revenue-grossing segment in the global uveitis treatment market in 2023 owing to the high prevalence of anterior uveitis, early onset symptoms, and the effectiveness of existing treatment options in managing this specific type of uveitis. For instance, in September 2022 Santen Pharmaceutical launched **IXINITY® (rifamycin SV) in Japan to treat uveitis. Additionally, the panuveitis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of systemic diseases associated with panuveitis, rising awareness leading to early diagnosis, and advancements in treatment options tailored specifically for panuveitis management.

By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global uveitis treatment market in 2023 owing to the increasing patient visits to hospitals for uveitis diagnosis and treatment, along with the availability of a wide range of pharmaceuticals and specialized care in hospital pharmacy settings. For instance, in August 2022, the pharmaceutical company Tarsier Pharma, which focuses on finding, developing, and bringing to market first-in-class pharmaceutical therapies to treat ocular diseases that cause blindness in the front and back of the eye, announced the development of TRS02, a potential immunomodulator, for the treatment of retinal diseases like posterior uveitis. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, accessibility, and increasing preference for online purchasing of pharmaceuticals, coupled with advancements in e-commerce platforms facilitating medication delivery to patients' doorsteps.

North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of uveitis, well-established healthcare infrastructure, increasing adoption of advanced treatment options, and strong support for research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing awareness about eye health, rising disposable incomes, and growing prevalence of uveitis in the region. For instance, in March 2023, Oculis S.A. introduced Kepivance® (ceftaroline fosamil) in Europe to treat endophthalmitis, an eye infection that can occasionally be a consequence of uveitis.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Treatment Type, Disease Type, and Distribution Channel
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players

Segmentation: Uveitis Treatment Market Report 2023 - 2034

Uveitis Treatment Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)

• Corticosteroids
• Immunosuppressant
• Monoclonal Antibodies
• Cycloplegic Agents
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

Uveitis Treatment Market Analysis & Forecast by Disease Type 2023 - 2034 (Revenue USD Bn)

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

Uveitis Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Uveitis Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA